Wiki source
Engineered Cell Therapies
A read-only view of this entry as wiki markup. This atlas is curated, so editing is disabled — but the source shows exactly how the page is structured.
# Engineered Cell Therapies Portal: Future Pharma Stage: Clinical practice in defined indications Evidence: Clinical practice Template: Drug platform Risk: High Reversibility: Difficult to reverse Last reviewed: Jun 2026 == Summary == Living cells engineered to fight disease have transformed some blood cancers and are being pushed toward solid tumors, autoimmunity, and off-the-shelf manufacturing. == Key takeaways == * CAR-T therapies produce durable remissions in some blood cancers that resisted other treatment. * Solid tumors and autoimmune disease are the expansion fronts, with early autoimmune results notable. * Cost, manufacturing, and serious immune toxicities constrain access and scale. == How engineered cells work == In CAR-T therapy, a patient's T cells are collected, engineered to express a receptor that recognizes a cancer marker, expanded, and reinfused. The living drug then proliferates and persists, attacking cells carrying the target. The same logic extends to other cell types and targets: engineered T cells against autoimmune B cells, natural killer cells, and stem-cell-derived products intended to be manufactured in advance rather than made per patient. == Frontier and constraints == The frontier is beyond blood cancer: durable responses in refractory autoimmune disease have drawn intense interest, and solid-tumor programs are working against a hostile tumor environment and antigen escape. The constraints are practical. Bespoke manufacturing is slow and expensive, toxicities such as cytokine release require specialized centers, and off-the-shelf allogeneic products must solve rejection and persistence. Scaling access is as much a manufacturing problem as a biology problem. == Open questions == * Can allogeneic 'off-the-shelf' products match bespoke cells on durability? * Will cell therapy work against common solid tumors, not just blood cancers? == Watchlist == * Autoimmune indications * Allogeneic manufacturing * Solid-tumor strategies == References == * FDA approval of first CAR-T therapy (Kymriah) — U.S. FDA, 2017. https://www.fda.gov/news-events/press-announcements/fda-approval-brings-first-gene-therapy-united-states. First approved CAR-T cell therapy in the United States. * CAR-T in refractory autoimmune disease — Müller et al., NEJM, 2024. https://www.nejm.org/doi/full/10.1056/NEJMoa2308917. Reported durable responses in severe autoimmune disease. == Categories == [[Category:Future Pharma]] [[Category:CAR-T]] [[Category:iPSC]] [[Category:immunotherapy]]